Immunotherapy or Targeted Therapy Versus Best Supportive Care for Advanced Gastric Cancer: A Systematic Review and Meta-analysis of Randomized Trials.

J Gastrointest Cancer · 2025 · PMC11876278 · PMID 40032744

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

[ 40 ], the addition of molecular targeted therapy (ramucirumab and everolimus, respectively) to BSC compared to placebo plus BSC showed a trend towards a slightly longer time to deterioration in global QoL.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.